Psychedelics in Europe in 2026: Portugal, the Netherlands, Switzerland and What “Legal” Really Means

Europe is often presented as if it has one liberal drug policy. It does not. Drug law remains largely national, and three countries that are frequently described as “psychedelic friendly” — Portugal, the Netherlands and Switzerland — actually use very different legal models.

Portugal: decriminalization, not legalization

Portugal’s Law 30/2000 changed the way personal possession and use of drugs are handled. Small quantities intended for personal use are generally addressed through an administrative health-oriented system rather than ordinary criminal prosecution. This approach was designed to reduce harms associated with criminalization and connect people with health and social services where needed.

But decriminalization does not create a legal commercial market. Unauthorized production, sale and trafficking remain offences. A visitor should not interpret Portugal’s policy as permission to buy LSD, MDMA or psilocybin from an unlicensed seller.

The Netherlands: why “magic mushrooms are legal” is outdated

In 2008, the Netherlands added hallucinogenic mushrooms to List II of the Opium Act. The law covered mushrooms that naturally contain psilocybin or psilocin, and official Dutch guidance makes clear that sale and other activities involving those mushrooms are prohibited.

Psychedelic truffles, technically sclerotia rather than mushrooms, have historically been treated differently. Dutch parliamentary answers confirmed that sclerotia were not included in the mushroom prohibition. This is a legal distinction about the biological material, not a general declaration that psilocybin is legal. Psilocybin and psilocin themselves remain controlled substances.

Switzerland: controlled access through exceptional licences

Switzerland provides an example of limited legal access without broad legalization. The Federal Office of Public Health can issue exceptional licences for scientific research and restricted medical use of prohibited narcotics. Swiss guidance specifically discusses LSD, psilocybin and MDMA in this exceptional-authorization system.

For limited medical use, the treating physician must apply, the patient must live in Switzerland, written consent is required, and the request is considered under strict clinical conditions. This is very different from a walk-in commercial service or unrestricted personal use.

What about the rest of Europe?

Across most European countries, LSD, MDMA and psilocybin remain controlled under national drug laws. Research may be possible under regulatory approval, and policy reforms continue to evolve, but there is no European Union-wide legalization of psychedelics. Rules for possession, thresholds, research, medical practice and penalties can differ substantially from one country to another.

Three words that should never be confused

Legalization means the law permits an activity within defined rules. Decriminalization usually means an activity remains prohibited but is no longer treated as a criminal offence in the same way. Medical authorization means a substance can be used only through a regulated healthcare pathway. These models have very different consequences for patients, clinicians and the public.

Sources checked

Swiss Federal Office of Public Health; Dutch Opium Act and Staatsblad 2008, 486; Dutch parliamentary answers on psychedelic sclerotia; Portuguese drug policy under Law 30/2000 and European drug-policy resources. Laws change, so this article should be treated as a dated educational overview, not legal advice.